Newleos Therapeutics
Chris Jepsen is a seasoned professional in the field of quality and compliance within the biopharmaceutical industry, currently serving as Head of Quality at Newleos Therapeutics since March 2025. Prior experience includes roles such as VP of Quality Systems and Compliance at Centessa Pharmaceuticals and VP of Global Quality, Systems and Compliance at Moderna. Chris has held significant positions at various organizations, including Senior Director of Corporate Quality and Compliance at Alexion Pharmaceuticals and Senior Compliance Director at Sanofi Genzyme. Earlier in the career, Chris gained valuable experience as Quality Operations Director at Genzyme Corporation and as a Naval Flight Officer in the United States Navy Reserve. Chris holds a Master’s degree in Environmental Engineering from Tufts University and a Bachelor’s degree in Biology from Norwich University.
This person is not in any teams
This person is not in any offices
Newleos Therapeutics
We are dedicated to providing a new dawn or "eos" for patients with mental health conditions by developing next generation, first- and best-in-class therapies. Over 100 million patients in the United States are affected by neuropsychiatric disorders, with anxiety and substance use disorders among the largest areas of unmet medical need. Our clinical-stage pipeline was licensed from Roche and includes oral small molecules targeting GABAA-γ1, V1a, TAAR1 and GABAA-α5 with broad potential in general anxiety, social anxiety, substance use disorders and cognitive impairment. Newleos was co-founded by Longwood Fund, Federico Bolognani, M.D., Ph.D., and William Martin, Ph.D., seasoned experts in company creation and CNS drug development.